Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old (including those who are exactly 70)
- You have been diagnosed with systemic lupus erythematosus (SLE, also known as lupus) based on recognised international diagnostic guidelines
- You are receiving or plan to receive treatment with a medicine called telitacicept
Who may not be able to join:
- You have been diagnosed with another disease affecting the immune system or joints (such as rheumatoid arthritis or similar conditions)
- You currently have an active infection, whether short-term (acute) or long-lasting (chronic)
- You are currently being treated with other biologic medicines (a type of medicine made from living cells — confirm with trial site if you are unsure whether your medication counts)
- You have a serious illness that causes significant weight loss or physical decline, such as cancer
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dong Lingli, MD, Tongji Hospital
Phone: 17742804229
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index （SELENA-SLEDAI）; Physician's Global Assessment; Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F); Serum anti-double stranded DNA (anti-dsDNA); Serum complement C3 levels; Serum complement C4 levels; Serum immunoglobulin quantification; Levels of C-reactive protein (CRP) levels; Levels of interleukin-10 (IL-10) levels; Levels of ferritin levels; the safety of telitacicept for SLE patients; the reasons for medication discontinuation; Levels of leukocyte levels; Levels of hemog...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.